PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP

Multi-agent AI is edging toward the pharmaceutical shop floor, and the question of where the human gate belongs in a validated GxP environment is no longer theoretical. In Part 2 of the three-part first episode of the PharmTech AI Pulse Check video series, Christopher Cole, associate editorial director, PharmTech, asks for insights from co-hosts Florin Muraru, an independent regulatory advisor; Gourav Pandey, R&D quality lead at Takeda; and Richard Jaenisch, senior director at Open Biopharm (Watch Part 1: Fixing AI Slop at the Source). The conversation opens with a recent benchmark test in which OpenAI agents reportedly built a private coordination channel days after it was shut down, and asks how pharma's segregation-of-duties playbook should respond.

Muraru argues that letting agents talk while requiring human sign-off before any action is realistic in a validated environment, but only if the action is the GxP-relevant step. He draws a firm line at batch release, noting, "The agents reasoning together is fine, but an agent releasing a batch without a human decision absolutely is out of limit." The real problem, he explains, emerges when inter-agent conversation becomes the basis of a decision, because that exchange then qualifies as a record carrying data integrity, retention, and review obligations. He adds a further regulatory layer: a self-modifying multi-agent system lacks a stable baseline to validate against, and validation underpins trust in computerized systems in GxP environments.

Pandey adds that data integrity culture in pharma treats even a sticky note as a GxP document, so an inter-agent discussion that was never captured is a serious gap. He points to two agents building a deviation report, one drafting the investigation while the other works through facts, and observes that machines can do a great deal of the work but a signature must belong to a real, answerable person. Jaenisch raises the architecture question: hash-chain audit logs and permission gates help, yet the benchmark agents went around those gates. He favors a monitoring agent over human reviewers because no one has time to read a week and a half of dense output.

The discussion then turns to Baidu's newly open-sourced model that parses entire multi-page documents, including tables, layout, and reading order, in a single pass. Pandey sees an opening for the decades of scanned records, handwritten logbooks, and research lab books sitting in third-party archival facilities. Because the model is open source, companies can deploy it in-house with a GPU and pair it with a knowledge graph linking terminated programs, old batches, and compliance reports to vendors, molecules, solvents, and raw materials. He finds particular promise for research, noting, "We have so many failed experiments that may have insightful information for the molecule which never progressed further down the line in the pipeline."

Muraru cautions that the moment those documents underpin a reconstructed batch record, data migration, or regulatory submission, the system leaves research territory and requires validation, since an OCR error can become a data integrity error. His advice is to use the tool for looking back at records but to verify against the originals. Jaenisch adds that many-to-many document analysis has historically been prohibitively expensive, that someone must define ground-truth documents so the model can tell signal from scrap, and that OCR across older, varied document types is a concern because generative AI reflects its training data. He places meaningful adoption a year or two away and quips that governing this architecture will create new jobs.